RMD Resmed Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RMD

Price (delayed)

$235.45

Market cap

$34.26B

P/E Ratio

74.51

Dividend/share

$1.56

EPS

$3.16

Enterprise value

$34.9B

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory ...

Highlights
Resmed's debt has decreased by 42% YoY and by 10% QoQ
The gross profit has grown by 8% YoY
RMD's equity is up by 20% year-on-year but it is down by 5% since the previous quarter
The price to earnings (P/E) is 89% higher than the 5-year quarterly average of 39.6 and 61% higher than the last 4 quarters average of 46.6
Resmed's quick ratio has decreased by 48% YoY and by 35% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.resmed.com/
Peers: MDT TMO MASI INGN

Key stats

What are the main financial stats of RMD
Market
Shares outstanding
145.52M
Market cap
$34.26B
Enterprise value
$34.9B
Valuations
Price to earnings (P/E)
74.51
Price to book (P/B)
12.65
Price to sales (P/S)
11.08
EV/EBIT
39.46
EV/EBITDA
32.44
EV/Sales
11.29
Earnings
Revenue
$3.09B
EBIT
$884.39M
EBITDA
$1.08B
Free cash flow
$747.68M
Per share
EPS
$3.16
Free cash flow per share
$5.14
Book value per share
$18.62
Revenue per share
$21.24
TBVPS
$15.46
Balance sheet
Total assets
$4.59B
Total liabilities
$1.88B
Debt
$868.8M
Equity
$2.71B
Working capital
$589.61M
Liquidity
Debt to equity
0.32
Current ratio
1.67
Quick ratio
0.86
Net debt/EBITDA
0.59
Margins
EBITDA margin
34.8%
Gross margin
58.2%
Net margin
14.8%
Operating margin
28.6%
Efficiency
Return on assets
10%
Return on equity
17%
Return on invested capital
37.9%
Return on capital employed
23.8%
Return on sales
28.6%
Dividend
Dividend yield
0.66%
DPS
$1.56
Payout ratio
49.4%

RMD stock price

How has the Resmed stock price performed over time
Intraday
-0.43%
1 week
11.08%
1 month
20.48%
1 year
39.33%
YTD
10.77%
QTD
21.35%

Financial performance

How have Resmed's revenue and profit performed over time
Revenue
$3.09B
Gross profit
$1.8B
Operating income
$885.29M
Net income
$457.24M
Gross margin
58.2%
Net margin
14.8%
Resmed's net margin has decreased by 35% QoQ and by 16% YoY
RMD's net income is down by 35% QoQ and by 11% YoY
RMD's operating income is up by 25% YoY
RMD's operating margin is up by 17% year-on-year

Growth

What is Resmed's growth rate over time

Valuation

What is Resmed stock price valuation
P/E
74.51
P/B
12.65
P/S
11.08
EV/EBIT
39.46
EV/EBITDA
32.44
EV/Sales
11.29
The price to earnings (P/E) is 89% higher than the 5-year quarterly average of 39.6 and 61% higher than the last 4 quarters average of 46.6
The EPS has decreased by 35% from the previous quarter and by 11% YoY
RMD's P/B is 65% above its 5-year quarterly average of 7.7 and 22% above its last 4 quarters average of 10.4
RMD's equity is up by 20% year-on-year but it is down by 5% since the previous quarter
The P/S is 69% higher than the 5-year quarterly average of 6.6 and 21% higher than the last 4 quarters average of 9.2
The company's revenue rose by 7% YoY

Efficiency

How efficient is Resmed business performance
The company's return on invested capital rose by 46% YoY and by 11% QoQ
Resmed's ROE has decreased by 37% from the previous quarter and by 28% YoY
The ROA has decreased by 35% from the previous quarter and by 17% YoY
The ROS has increased by 25% YoY and by 2.5% from the previous quarter

Dividends

What is RMD's dividend history
DPS
$1.56
Dividend yield
0.66%
Payout ratio
49.4%
Recent dividends

Financial health

How did Resmed financials performed over time
The company's total assets is 144% higher than its total liabilities
Resmed's quick ratio has decreased by 48% YoY and by 35% from the previous quarter
The current ratio has contracted by 37% YoY and by 33% from the previous quarter
Resmed's debt is 68% lower than its equity
Resmed's debt to equity has shrunk by 52% YoY and by 6% QoQ
Resmed's debt has decreased by 42% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.